多参数MRI作为局限性前列腺癌新辅助治疗反应生物标志物的初步研究
前瞻性研究纳入8例局限性前列腺癌患者,基线和6个月雄激素剥夺治疗后各行一次多参数MRI,随后行前列腺切除术。治疗后肿瘤区Ktrans和AUC90下降而ADC无变化,MRI与病理残余癌负荷无差异且正相关,提示多参数MRI可能作为治疗反应生物标志物和病理残余癌负荷的替代指标。
要点
- 基线肿瘤区ADC低于正常区,Ktrans和AUC90高于正常区。
- 6个月雄激素剥夺治疗后肿瘤区Ktrans和AUC90下降,ADC无变化。
- MRI与病理残余癌负荷正相关,提示多参数MRI可能作为治疗反应生物标志物。
核心结论
- 考虑到前列腺癌的异质性,个体化雄激素剥夺治疗可能最大化潜在获益。
- 本初步研究提示多参数MRI可能作为雄激素剥夺治疗反应的生物标志物,并作为前列腺切除标本残余癌负荷的替代指标。
研究设计与样本
- 前瞻性研究,经机构审查委员会批准并符合HIPAA,纳入8例局限性前列腺癌患者。
- 患者基线行多参数MRI,雄激素剥夺治疗6个月后重复多参数MRI,随后行前列腺切除术。
- 从肿瘤和正常感兴趣区提取多参数MRI指标,并在多参数MRI和前列腺切除标本上测量残余癌负荷。
关键影像表现/征象
- 基线肿瘤区ADC低于正常区(806 ± 137 × 10-6 vs. 1277 ± 213 × 10-6 mm2/sec,p = 0.0005)。
- 基线肿瘤区Ktrans高于正常区(0.346 ± 0.16 vs. 0.144 ± 0.06 min-1,p = 0.002),AUC90亦高于正常区(0.213 ± 0.08 vs. 0.11 ± 0.03,p = 0.002)。
- 治疗后肿瘤区Ktrans由0.346 ± 0.16降至0.188 ± 0.08 min-1(p = 0.02),AUC90由0.213 ± 0.08降至0.13 ± 0.06(p = 0.02),肿瘤区ADC无变化。
- 雄激素剥夺治疗后肿瘤体积减小。
诊断标准与关键数值
- 多参数MRI基于的残余癌负荷与病理基于的残余癌负荷无差异,两者正相关(⍴ = 0.74-0.81,p < 0.05)。
- 病理基于的残余癌负荷与治疗后DCE指标正相关(⍴ = 0.76-0.70,p < 0.05),与ADC负相关(⍴ = -0.79,p = 0.03)。
临床应用与阅片要点
- 本初步研究提示多参数MRI可能作为雄激素剥夺治疗反应的生物标志物,并作为前列腺切除标本残余癌负荷的替代指标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To explore a role for multiparametric MRI (mpMRI) as a biomarker of response to neoadjuvant androgen deprivation therapy (ADT) for prostate cancer (PCa).
MATERIALS AND METHODS: This prospective study was approved by the institutional review board and was HIPAA compliant. Eight patients with localized PCa had a baseline mpMRI, repeated after 6-months of ADT, followed by prostatectomy. mpMRI indices were extracted from tumor and normal regions of interest (TROI/NROI). Residual cancer burden (RCB) was measured on mpMRI and on the prostatectomy specimen. Paired t-tests compared TROI/NROI mpMRI indices and pre/post-treatment TROI mpMRI indices. Spearman's rank tested for correlations between MRI/pathology-based RCB, and between pathological RCB and mpMRI indices.
RESULTS: At baseline, TROI apparent diffusion coefficient (ADC) was lower and dynamic contrast enhanced (DCE) metrics were higher, compared to NROI (ADC: 806 ± 137 × 10-6 vs. 1277 ± 213 × 10-6 mm2/sec, p = 0.0005; Ktrans: 0.346 ± 0.16 vs. 0.144 ± 0.06 min-1, p = 0.002; AUC90: 0.213 ± 0.08 vs. 0.11 ± 0.03, p = 0.002). Post-treatment, there was no change in TROI ADC, but a decrease in TROI Ktrans (0.346 ± 0.16 to 0.188 ± 0.08 min-1; p = 0.02) and AUC90 (0.213 ± 0.08 to 0.13 ± 0.06; p = 0.02). Tumor volume decreased with ADT. There was no difference between mpMRI-based and pathology-based RCB, which positively correlated (⍴ = 0.74-0.81, p < 0.05). Pathology-based RCB positively correlated with post-treatment DCE metrics (⍴ = 0.76-0.70, p < 0.05) and negatively with ADC (⍴ = -0.79, p = 0.03).
CONCLUSION: Given the heterogeneity of PCa, an individualized approach to ADT may maximize potential benefit. This pilot study suggests that mpMRI may serve as a biomarker of ADT response and as a surrogate for RCB at prostatectomy.
引用
- Fennessy FM, Fedorov A, Vangel MG, et al. Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer-A Pilot Study. Acad Radiol. 2019. PMID: 31862185. doi:10.1016/j.acra.2019.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。